A For­bion-fund­ed start­up bought the rights to Am­gen's CETP in­hibitor, and is giv­ing the cho­les­terol drug an­oth­er go

For­bion-fund­ed start­up NewAms­ter­dam Phar­ma has ac­quired the rights to obice­trapib: the CETP in­hibitor that CEO Michael David­son al­ways thought would be the “crown­ing” of his …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER